Fungal disease diagnosis is lifesaver for patients with HIV and AIDS
April 12 2021
A fungal disease diagnostic and educational programme has had a transformational impact on the mortality of HIV patients in Guatemala, according to new research. The programme, say scientists at the Asociación de Salud Integral (ASI) in Guatemala City and The University of Manchester, will save lives in countries across the developing world if implemented. The study is published in the Journal of Fungi and funded by The Global Action Fund for Fungal Infections.
- Read the paper: Medina et al (2021)
The research team studied 2127 Guatemalan HIV patients between the ages of 25 and 41, of which 385 (18%) had a life-threatening fungal infection or tuberculosis. The Mayan ethnic group in Guatemala had a high rate of advanced HIV disease – 65%.
Histoplasmosis – caused by a fungus called Histoplasma – was the most frequent infection (7.9%), followed by tuberculosis (7.1%) and cryptococcosis (4.8%) – which is often confused with fungal disease. Some patients had 2 or 3 concurrent infections. The team found that infection gave a 5-fold greater chance of dying; however, overall the program decreased mortality by 7%. This reduction was achieved by rapid diagnosis and earlier, appropriate treatment.
Guatemala has the worst record of identifying and treating HIV disease early in the Americas, resulting in the large numbers of people with severe disease. Without diagnostic and educational support, doctors, they argue, are more likely to base their diagnosis on guesswork often resulting in an incorrect diagnosis.
“This diagnostic and educational program has been transformational for patients with HIV in Guatemala – inspiring confidence in our healthcare workers, providing rapid diagnostic answers in complex medical cases and saving lives.”
- Dr Eduardo Arathoon (The Program Director at ASI, a non-profit organization that specializes in HIV and infectious diseases)
Guatemala has a high incidence of Histoplasma, which grows in soil and bat caves. Rapid testing in the urine or blood is critical for choosing antifungal treatment – the mistaken diagnosis of tuberculosis is all too common, leading to a patient’s death. Other hyperendemic areas for Histoplasma include the Guiana Shield, other Central American and Caribbean countries, Myanmar, Thailand and parts of the Philippines and Indonesia, as well as the Mississippi Basin in the USA.
“We believe this is this first population-level demonstration of the power of diagnostics for fungal disease to saves lives. The combination of rapid diagnostic testing, expert training, online and mobile test ordering and reporting clearly show a survival benefit. More patients with AIDS die of the fungal disease than tuberculosis, and we show that rapid diagnosis can save their lives. We hope other communities and countries can adopt simar approaches.”
- Dr David Denning (Professor of Infectious Diseases in Global Health at The University of Manchester and Chief Executive of the Global Action Fund for Fungal Infections)